StockData
Teva Pharmaceutical Industries Ltd logo

Teva Pharmaceutical Industries Ltd

TEVANYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30127% above fair value
$42.23−0.39 (-0.92%)

Close on Nov 18, 2026Market cap $49.21BP/E 70.4Yield –

Teva Pharmaceutical Industries Teva API (TAPI) by Quarter

Teva API (TAPI) — Active Pharmaceutical Ingredient Sales to Third Parties ($M)

Teva Pharmaceutical Industries Teva API (TAPI): $115M in Q3 2026, down 8.0% from a year earlier.

Latest, Q3 2026
115
Period ended Sep 30, 2026
Change on a year earlier
-8.0%
125 in Q3 2025
History
32 quarters
Since Q1 2018
Sources
32
Documents cited below

Where the Q3 2026 figure comes from

“API sales to third parties in the third quarter of 2026 were $115 million, a decrease of 8% in both U.S. dollars and local currency terms, compared to the third quarter of 2025. This decrease was mainly due to lower dema”

Source: Form 8-K Earnings Release (0001171843-26-007054) ↗

Third-party revenues of Teva Active Pharmaceutical Ingredients (TAPI), one of the world's leading suppliers of APIs.

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedTeva API (TAPI) — Active Pharmaceutical Ingredient Sales to Third Parties ($M)Year on yearSource
Q3 2026Sep 30, 2026115-8.0%Form 8-K Earnings Release (0001171843-26-007054) ↗
Q2 2026Jun 30, 2026118-12.6%Form 8-K Earnings Release (0001171843-26-004974) ↗
Q1 2026Mar 31, 2026109-16.2%Form 8-K Earnings Release (0001171843-26-002796) ↗
Q4 2025Dec 31, 2025136-6.2%Form 8-K Earnings Release (0001171843-26-000462) ↗
Q3 2025Sep 30, 2025125-3.8%Form 10-Q (0001193125-25-266895) ↗
Q2 2025Jun 30, 2025135-10.6%Form 8-K Earnings Release (0001171843-25-004808) ↗
Q1 2025Mar 31, 2025130+1.6%Form 8-K Earnings Release (0001171843-25-002849) ↗
Q4 2024Dec 31, 2024145–Form 8-K Earnings Release (0001171843-25-000493) ↗
Q3 2024Sep 30, 2024130-0.8%Form 8-K Earnings Release (0001171843-24-006034) ↗
Q2 2024Jun 30, 2024151-0.7%Form 8-K Earnings Release (0001171843-24-004270) ↗
Q1 2024Mar 31, 2024128-3.0%Form 10-Q (0001193125-24-134200) ↗
Q3 2023Sep 30, 2023131-12.1%Form 10-Q (0001193125-23-274495) ↗
Q2 2023Jun 30, 2023152-14.1%Form 8-K Earnings Release (0001193125-23-201707) ↗
Q1 2023Mar 31, 2023132-27.1%Form 10-Q (0001193125-23-140697) ↗
Q3 2022Sep 30, 2022149-7.5%Form 10-Q (0001193125-22-276883) ↗
Q2 2022Jun 30, 2022177-11.1%Form 10-Q (0001193125-22-203392) ↗

Breakdown

What makes up teva API (TAPI)

Cite this data

StockData. (2026). Teva Pharmaceutical Industries Teva API (TAPI) ($M), quarterly Q1 2018–Q3 2026 [Data set]. Compiled from Teva Pharmaceutical Industries SEC filings and investor materials. https://stockdatahq.com/stocks/teva/kpis/sub-tapi-rev

See every metric in the Teva Pharmaceutical Industries KPI table. Data updated Nov 10, 2026.

See a number that looks wrong?